Klabax (Clarithromycin)

Clarithromycin is a macrolide antibiotic indicated for several bacterial infections affecting the respiratory tract, sinuses, skin and gastrointestinal system.

• Community‑acquired pneumonia: effective in treating typical and atypical bacterial causes, improving clinical outcomes.
• Acute bacterial sinusitis: reduces sinus inflammation and bacterial load, facilitating symptom relief.
• Skin and soft‑tissue infections: targets Gram‑positive and some Gram‑negative organisms, aiding resolution of cellulitis and wound infections.
• Helicobacter pylori eradication: used in combination therapy to eliminate H. pylori infection and prevent ulcer recurrence.
• Other susceptible bacterial infections: employed where the causative pathogen is known to be sensitive to macrolides.

• Clarithromycin exerts its antibacterial effect by binding to the 50S subunit of bacterial ribosomes. This interaction blocks the translocation step of protein synthesis, preventing elongation of the peptide chain and thereby inhibiting bacterial growth. The drug’s high affinity for the ribosomal binding site confers a bacteriostatic activity against a broad spectrum of Gram‑positive, Gram‑negative and atypical organisms. It also penetrates well into respiratory tissues, achieving concentrations above the minimum inhibitory concentrations for common pathogens.

Clarithromycin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild stomach upset often occurring after the first dose.
• Diarrhea: loose stools that may be self‑limiting.
• Abdominal pain: cramping or discomfort in the stomach area.
• Taste disturbance: altered or metallic taste sensation.
• Headache: transient mild headache.

Serious or Rare Side Effects

• Hepatotoxicity: signs of liver injury such as jaundice or elevated enzymes.
• Cardiac arrhythmia: QT interval prolongation leading to irregular heartbeat.
• Severe allergic reaction: rash, itching, swelling, or anaphylaxis.
• Clostridioides difficile infection: severe colitis presenting with watery diarrhea.
• Pseudomembranous colitis: inflammation of the colon due to bacterial overgrowth.

When prescribing clarithromycin, clinicians should consider several precautionary measures to ensure safe use.

• Assess liver function: evaluate hepatic enzymes before initiating therapy in patients with liver disease.
• Monitor cardiac risk: avoid use in patients with known QT prolongation or electrolyte disturbances.
• Review drug history: consider potential interactions with drugs metabolized by CYP3A4.
• Adjust in renal impairment: dose may need modification in severe renal dysfunction.
• Counsel on gastrointestinal effects: advise patients to report persistent diarrhea or abdominal pain.
• Store at ambient temperature: keep tablets in original packaging, protect from moisture and heat.

Clarithromycin interacts with several medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may cause toxic levels of clarithromycin.
• Certain statins (e.g., simvastatin, lovastatin): increased risk of rhabdomyolysis.
• Antiarrhythmic agents (e.g., amiodarone): heightened risk of QT prolongation.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Theophylline: possible increased plasma concentrations, monitor for toxicity.
• Carbamazepine: may reduce clarithromycin levels, decreasing efficacy.